CHICAGO--(BUSINESS WIRE)--Syntax Bio, a synthetic biology company programming next generation cell therapies, today announced a research and development collaboration with Mayo Clinic focused on ...
Sangamo Therapeutics, a pioneering gene editing biotech company in the Bay Area, has filed for Chapter 11 bankruptcy protection and agreed to sell some of its programs and platforms to Eli Lilly and ...
The mechanical process of cell division exerts powerful, if microscopic, forces. How do the molecular machines that power it ...
EULAR data demonstrated potential for immune reset, including remissions, in both systemic lupus erythematosus (SLE) and ...
Johnson & Johnson has paid $1 billion upfront to buy itself a degrader antibody conjugate (DAC) platform via the acquisition of Firefly Bio. DACs sit at the intersection of antibody-drug conjugates ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results